MHLW To Consider Switch Of 19 Drugs to OTC, Including 12 Hypertension Products
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As a means to reduce national healthcare costs, Japan's Ministry of Health, Labor and Welfare June 7 released 19 pharmaceutical drugs for deliberation by its policy commission as potential switches to over-the-counter pharmaceuticals. The list included 12 hypertension drugs to be sold OTC, believed to be the first time in the world
You may also be interested in...
Japan Paves Way For Pfizer/Wyeth's Viviant To Hit Crowded Osteo Space
The First Subcommittee on New Drugs at Japan's Ministry of Health June 3 recommended six drugs for approval, including Wyeth/Pfizer's Viviant (bazedoxifene), clearing a hurdle for the merged companies' lead selective estrogen reuptake modulator for postmenopausal osteoporosis in Japan's crowded market
Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market
SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).